Skip to main content
×
Blacklisted Listed News Logo
Menu - Navigation
Menu - Navigation

Cited Sources

2nd Smartest Guy in the World
2nd Amendment Shirts
10th Amendment Center
Aaron Mate
Activist Post
AIER
Aletho News
Ammo.com
AmmoLand
Alliance for Natural Health, The
Alt-Market
American Free Press
Antiwar
Armstrong Economics
Art of Liberty
AUTOMATIC EARTH, The
Ben Bartee
Benny Wills
Big League Politics
Black Vault, The
BOMBTHROWER
Brandon Turbeville
Breaking Defense
Breitbart
Brownstone Institute
Burning Platform, The
Business Insider
Business Week
Caitlin Johnstone
Campus Reform
CAPITALIST EXPLOITS
Charles Hugh Smith
Children's Health Defense
CHRISTOPHE BARRAUD
Chris Wick
CIAgate
Citizen Free Press
Citizens for Legit Gov.
CNN Money
Collective Evolution
Common Dreams
Conscious Resistance Network
Corbett Report
Counter Signal, The
Cryptogon
Cryptome
Daily Bell, The
Daily Reckoning, The
Daily Veracity
DANERIC'S ELLIOTT WAVES
Dark Journalist
David Haggith
Defense Industry Daily
Defense Link
Defense One
Dennis Broe
DOLLAR COLLAPSE
DR. HOUSING BUBBLE
Dr. Robert Malone
Drs. Wolfson
Drudge Report
Economic Collapse, The
ECONOMIC POPULIST, The
Electronic Frontier Foundation
Ellen Brown
Emerald Robinson
Expose, The
F. William Engdahl
FAIR
Farm Wars
Faux Capitalist
FINANCIAL REVOLUTIONIST
Forbes
Foreign Policy Journal
FOREXLIVE
Foundation For Economic Freedom
Free Thought Project, The
From Behind Enemy Lines
From The Trenches
FUNDIST
Future of Freedom Foundation
Futurism
GAINS PAINS & CAPITAL
GEFIRA
Geopolitical Monitor
Glenn Greenwald
Global Research
Global Security
GM RESEARCH
GOLD CORE
Grayzone, The
Great Game India
Guadalajara Geopolitics
Helen Caldicott
Homeland Sec. Newswire
Human Events
I bank Coin
IEEE
IMPLODE-EXPLODE
Information Clearing House
Information Liberation
Infowars
Insider Paper
Intel News
Intercept, The
Jane's
Jay's Analysis
Jeff Rense
John Adams
John Pilger
John W. Whitehead
Jonathan Cook
Jon Rappoport
Jordan Schachtel
Just The News
Kevin Barret
Kitco
Last American Vagabond, The
Lew Rockwell
Le·gal In·sur·rec·tion
Libertarian Institute, The
Libertas Bella
LIBERTY BLITZKRIEG
LIBERTY Forcast
Liberty Unyielding
Market Oracle
Market Watch
Maryanne Demasi
Matt Taibbi
Medical Express
Media Monarchy
Mercola
Michael Snyder
Michael Tracey
Middle East Monitor
Mike "Mish" Shedlock
Military Info Tech
Mind Unleashed, The
Mint Press
MISES INSTITUTE
Mises Wire
MISH TALK
Money News
Moon of Alabama
Motherboard
My Budget 360
Naked Capitalism
Natural News
New American, The
New Eastern Outlook
News Deck
New World Next Week
Nicholas Creed
OF TWO MINDS
Off-Guardian
Oil Price
OPEN THE BOOKS
Organic Prepper, The
PANDEMIC: WAR ROOM
PETER SCHIFF
Phantom Report
Pierre Kory
Political Vigilante
Public Intelligence
Rair
Reclaim The Net
Revolver
Richard Dolan
Right Turn News
Rokfin
RTT News
Rutherford Institute
SAFEHAVEN
SAKER, The
Shadow Stats
SGT Report
Shadowproof
Slay News
Slog, The
SLOPE OF HOPE
Solari
South Front
Sovereign Man
Spacewar
spiked
SPOTGAMMA
Steve Kirsch
Steve Quayle
Strange Sounds
Strike The Root
Summit News
Survival Podcast, The
Tech Dirt
Technocracy News
Techno Fog
Terry Wahls, M.D.
TF METALS REPORT
THEMIS TRADING
Tom Renz
True Activist
unlimited hangout
UNREDACTED
Unreported Truths
Unz Review, The
VALUE WALK
Vigilant Citizen
Voltaire
Waking Times
Wall Street Journal
Wallstreet on Parade
Wayne Madsen
What Really Happened
Whitney Webb
winter oak
Wolf Street
Zero Hedge

The Corruptions of Pharma as a Service

Published: December 8, 2021 | Print Friendly and PDF
  Gab
Share

In the last few years, business models known as “X-as-a-Service” flourished. Most major companies turned their previous one-time products into subscription-based ones, improving, they said, customer retention. 

Investors loved the reliable cash flows, and every industry got on the hype train. Everyone from the ever-ephemeral corporate speak in earnings calls and quarterly reports to hedge funds and investment bank analysts started talking about “BaaS” (Banking as a service), “SaaS” (Software as a service), “GaaS” (Gaming as a service), or “DaaS” (Data as a service). 

During the many ransomware attacks earlier this year, experts monitoring that dark market even started to describe the opaque mechanisms behind organizing ransomware attacks as Ransomware-as-a-service, RaaS. Forbes and others have branded this new business doctrine the “As a Service”-revolution (XaaS). 

Let’s launch another mildly distasteful acronym: PaaS – Pharma as a Service. 

The structure of pharmaceutical products in the U.S. and many other Western countries relies on the precautionary principle: before a drug is approved and launched on the market, it must go through several rounds of testing. The drug has to be safe, at least relative to the condition it is intended to ameliorate, and effective at doing that. 

The ones that mostly make waves outside that industry are “Stage III” trials – usually large, usually double-blind, randomized control trials of some new medicine. Before the FDA approves it for use, pharma companies must show that the drug “provide[s] benefits that outweigh its known and potential risks for the intended population.

The process is slow, costly, lengthy, bureaucratic, and with high risk for the submitting pharmaceutical company. If the drug fails, or gets delayed, that’s millions and millions down the drain for your average pharma company. This means that it’s almost only pharmaceutical players with deep pockets that can afford to simultaneously fund and support enough trials to reap some of those juicy rewards of future drug patents. 

Willing participants can’t always get access to what seems to be a functioning drug, sometimes not even when their circumstances are so dire that the risks are warranted. The process most certainly means that successfully developing a drug is in the billions of dollars.

What if they could speed up the process and convince the wider public that everyone needs this new product? In a single shot – pun intended – massively expand the market for their novel product. What if, even better, it seems that everyone also needs supplements of this drug every six months or so?

Just to be clear, I’m not arguing fault here – or some conspiratorial set- up. I have no reason to believe that there were darker forces at play in the last year or pretend that we have some sort of smoking gun (“Big Pharma orchestrated the pandemic!”). Such stories are very rarely right, and shocking if even a little bit true.  

But think about the numbers for a minute. And consider whether this is a Bootleggers-and-Baptists situation going on. 

During the pandemic, the pharmaceutical giant Pfizer quadrupled its revenues from vaccines, and is now looking at $33.5 billion in 2021 from Covid vaccine sales alone (for comparison, a normal pre-pandemic year Pfizer averaged around $50bn in revenue, across all its products). The Covid vaccines indeed look like a juicy boost. 

Rebecca Robbins and Peter Goodman report for the New York Times that the U.S. paid Pfizer around $20 per dose delivered, with Israel even worse with $30 per dose. Pfizer expects to deliver about 2 billion doses this year, at somewhere between $10-$15 in revenue per dose (as it shares revenue with BioNTech) for a neat $20 or $30 billion of revenue – a 40-60% boost to pre-pandemic revenue. 

Naturally, many of these payments are politically induced in order to encourage manufacturers to rapidly scale production; Big Pharma can’t expect to receive that sort of hefty payoff forever. But if we convince enough people to take booster shots, say, every six months – or better yet, have governments mandate them in search of some laudable goal, Bootleggers and Baptists style – the vaccine producer still gets access to an entirely new market, massive and with beautifully recurring revenues. Pharma as a Service. Every six months, another brand new and shiny pharma needle goes into a few billion arms. Ka-Ching.

In all fairness, they won’t be able to reap the financial benefits that governments around the world have thrown at them every year going forward. For argument’s sake, let’s stipulate a slightly lower rate as a more believable long-term market rate, say $5 per dose.

Like with all subscription services, some people will opt out; others are too weak, too old, or too young (though, with vaccines for kids we’re solving that problem!); and others yet will refuse to submit. So perhaps the equilibrium service evens out at a billion doses a year, for $5 billion of revenue annually. Not revolutionary for a company that sells pharma products for $50bn a year – but not chicken-change either (especially as at least Pfizer’s profit margins on Covid vaccines look very attractive). 

What’s most disturbing, of course, is that the very media outlets least likely to approve of pharmaceutical companies making billions – The New York Times, The Guardian, MSNBC etc – are the ones loudest shouting for vaccine mandates. On the other hand, they run articles denouncing the many billions that pharma companies are making from Covid vaccines (here, here, or here). 

Which, one might ask, is it going to be?

All they had to do for the chips to fall where they did was to convince enough people and politicians that this was a terrible disease, that no other protection works, and that recurring booster shots are the only “scientific” way out.

 Of the many odd events in the last 20 months is that the CDC still refuses to offer practical advice that seems to work well – go outside, get exercise, ensure you’re not Vitamin-D deficient. To quote Bret Weinstein, a pariah of the corporate press, why are we not picking the low-hanging fruit before we go after excessively complicated and poorly working medical interventions like rushed and experimental vaccines?

Why should we unquestioningly believe a government that has routinely, incessantly, and carelessly hid information, issued faulty claims, and at every step of the way prevented truthful and accurate information from reaching the public?

Plenty of other medications seem to have a protective effect against Covid-19 and many of its consequences. The laughable “horse dewormer” debacle over Ivermectin is a good example. A recent study in The Lancet shows that Fluvoxamine, another cheap and readily available drug, seems to work well against Covid. What do these treatments have in common? They’re cheap, off-label, widely accessible – and don’t massively boost the revenue of Big Pharma. 

None of this is proof of foul play, but it sure feels like the circumstantial evidence is piling up. I’m not saying we have a smoking gun. I’m not saying there were dark rooms with despicable people smoking cigars and dreaming about billions of new pharma dollars. But given the corruption in American politics, in its bureaucracy, and most importantly in its media and academic establishments, is it inconceivable to suggest that maybe Big Pharma wanted its share of the as-a-Service-revolution?

Read More...

 

TOP TRENDING ARTICLES


PLEASE DISABLE AD BLOCKER TO VIEW DISQUS COMMENTS

Ad Blocking software disables some of the functionality of our website, including our comments section for some browsers.


Trending Now



BlackListed News 2006-2023
Privacy Policy
Terms of Service